HCPCS Level II code J3262 designates a 1 mg injectable unit of tocilizumab, a monoclonal antibody used in multiple inflammatory and immune-mediated conditions. Nationally, accurate reporting of unit-based HCPCS drug codes is critical for drug utilization tracking, reimbursement accuracy, and clinical inventory management given the high cost and weight-based dosing of many biologics. This publication analyzes coverage and billing considerations for major national payers.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, typical billing practices for unit-dosed injectable biologics, and common modifiers used in practice. The report also outlines clinical context for tocilizumab administration and where to expect site-of-service billing (outpatient infusion centers, physician offices, and hospital outpatient departments).

The content provides benchmarks and practical insights into service line implications, claims processing nuances for HCPCS Level II drug codes, and considerations for coding unit-based injectable biologics. Data not available in the input for some payer-specific policy details or utilization metrics is noted in relevant sections.